P. Wolkenstein et al., Quality-of-life impairment in neurofibromatosis type 1 - A cross-sectionalstudy of 128 cases, ARCH DERMAT, 137(11), 2001, pp. 1421-1425
Background: Neurofibromatosis type I affects quality of life (QoL) through
association with severe complications, impact on cosmetic features, and unc
ertainty of the effects of the disorder.
Objective: To evaluate the impact of the severity and visibility of neurofi
bromatosis type 1 on QoL.
Design: Monocenter, cross-sectional study.
Setting: One French academic dermatological and neurofibromatoses clinic.
Patients: A total of 128 adult patients with neurofibromatosis type 1.
Main Outcome Measures: Evaluation of severity and visibility using, respect
ively, the Riccardi and Ablon scales. Evaluation of skin disease-specific a
nd general QoL using, respectively, Skindex-France and SF-36 (Short Form 36
health survey) profiles controlled for sex, age, severity, and visibility.
Results: In a multiple regression model controlling for sex, age, and visib
ility, visibility remained independently associated with the alteration of
3 aspects of the skin disease-specific QoL (Skindex-France): emotions, phys
ical symptoms, and functioning (P=.03, P=.009, and P=.002, respectively). P
atients with more severe neurofibromatosis reported more effects on the fol
lowing domains of their general health QoL (SF-36): physical function, bodi
ly pain, general health perception, and vitality (P=.006, P=.03, P=.01, and
P=.04, respectively).
Conclusions: Neurofibromatosis type 1 has a significant impact on QoL throu
gh alteration of health and appearance. The consequences of visibility and
severity from the viewpoint of patients can be evaluated using Skindex and
the SF-36, respectively.